JOURNAL OF SHANDONG UNIVERSITY(NATURAL SCIENCE) ›› 2024, Vol. 59 ›› Issue (11): 51-63.doi: 10.6040/j.issn.1671-9352.0.2023.504

Previous Articles    

Effect of oxidative stress on a cysteine-conjugated antibody-drug conjugate

QU Yaocheng1,2, YAO Xuejing2, SUN Yundong1   

  1. 1. School of Basic Medical Sciences, Shandong University, Jinan 250012, Shandong, China;
    2. RemeGen Co., Ltd., Yantai 264006, Shandong, China
  • Published:2024-11-29

PDF (PC)

12

Abstract: We investigated the effects of oxidative stress on the structure and function of a cysteine(Cys)-conjugated antibody-drug conjugate(ADC). The research object was a Cys-conjugated, c-Met ADC(referred to as c-Met ADC). Firstly, the samples were incubated in different proportions of H2O2 solution for forced oxidation. Then, multiple analytical techniques were used to deeply characterize the structural and functional changes of the oxidized samples. H2O2 induced oxidative stress resulted in Met oxidation on the c-Met ADC antibody backbone and thioether bond cleavage in the linker. Met oxidation further led to a decrease in the thermal stability and neonatal Fc receptor(FcRn)affinity of the c-Met ADC, which were mainly related to Met257 oxidation on the antibody Fc. The cleavage of thioether bonds led to a decrease in the biological activity of the c-Met ADC. Oxidative stress was a key influencing factor on the stability of c-Met ADC, and the Met257 oxidation and thioether bond cleavage caused by it should be strictly monitored as its critical quality attributes in daily release and stability studies. At the same time, it should also be avoided to be exposed to oxidative environments or to mitigate the impact of oxidative stress on its structure and function by optimizing environmental factors.

Key words: antibody-drug conjugate, oxidative stress, forced degradation, methionine oxidation, off-target toxicity

CLC Number: 

  • R917
[1] FU Z W, LI S J, HAN S F, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy[J]. Signal Transduction and Targeted Therapy, 2022, 7:93.
[2] TSUCHIKAMA K, AN Z Q. Antibody-drug conjugates: recent advances in conjugation and linker chemistries[J]. Protein & Cell, 2018, 9(1):33-46.
[3] MCKERTISH C M, KAYSER V. Advances and limitations of antibody drug conjugates for cancer[J]. Biomedicines, 2021, 9(8):872.
[4] CHAU C H, STEEG P S, FIGG W D. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394:793-804.
[5] MAECKER H, JONNALAGADDA V, BHAKTA S, et al. Exploration of the antibody-drug conjugate clinical landscape[J]. mAbs, 2023, 15(1):2229101.
[6] WANG Z J, LI H X, GOU L T, et al. Antibody-drug conjugates: recent advances in payloads[J]. Acta Pharmaceutica Sinica B, 2023, 13(10):4025-4059.
[7] NOWAK C, CHEUNG J K, DELLATORE S M, et al. Forced degradation of recombinant monoclonal antibodies: a practical guide[J]. mAbs, 2017, 9(8):1217-1230.
[8] AGRAWAL N, CHENNAMSETTY N. Understanding, predicting, and mitigating the impact of post-translational physicochemical modifications, including aggregation, on the stability of biopharmaceutical drug products[M] //Developability of Biotherapeutics. Leiden: CRC Press, 2015:61-84.
[9] LUO Q Z, CHUNG H H, BORTHS C, et al. Structural characterization of a monoclonal antibody-maytansinoid immunoconjugate[J]. Analytical Chemistry, 2016, 88(1):695-702.
[10] BUECHELER J W, WINZER M, WEBER C, et al. Oxidation-induced destabilization of model antibody-drug conjugates[J]. Journal of Pharmaceutical Sciences, 2019, 108(3):1236-1245.
[11] CHEN Y, DOUD E, STONE T, et al. Rapid global characterization of immunoglobulin G1 following oxidative stress[J]. mAbs, 2019, 11(6):1089-1100.
[12] BOLL B, BESSA J, FOLZER E, et al. Extensive chemical modifications in the primary protein structure of IgG1 subvisible particles are necessary for breaking immune tolerance[J]. Molecular Pharmaceutics, 2017, 14(4):1292-1299.
[13] LIU D J, REN D, HUANG H, et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation[J]. Biochemistry, 2008, 47(18):5088-5100.
[14] LIU H C, GAZA-BULSECO G, XIANG T, et al. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody[J]. Molecular Immunology, 2008, 45(3):701-708.
[15] BERTOLOTTI-CIARLET A, WANG W R, LOWNES R, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors[J]. Molecular Immunology, 2009, 46(8/9):1878-1882.
[16] BURKITT W, DOMANN P, OCONNOR G. Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry[J]. Protein Science, 2010, 19(4):826-835.
[17] MO J J, YAN Q R, SO C K, et al. Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen/deuterium exchange mass spectrometry[J]. Analytical Chemistry, 2016, 88(19):9495-9502.
[18] STRACKE J, EMRICH T, RUEGER P, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies[J]. mAbs, 2014, 6(5):1229-1242.
[19] GAO X, JI J A, VEERAVALLI K, et al. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation[J]. Journal of Pharmaceutical Sciences, 2015, 104(2):368-377.
[20] FISHKIN N, MALONEY E K, CHARI R V J, et al. A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates(ADCs)under oxidative conditions[J]. Chemical Communications, 2011, 47(38):10752-10754.
[21] ZHU Y W, LIU K, WANG K L, et al. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis[J]. Cancer, 2023, 129(2):283-295.
[22] GLOVER Z K, WECKSLER A, ARYAL B, et al. Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species[J]. mAbs, 2022, 14(1):2122957.
[23] YAN B X, YATES Z, BALLAND A, et al. Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage[J]. The Journal of Biological Chemistry, 2009, 284(51):35390-35402.
[24] AKBARIAN M, CHEN S H. Instability challenges and stabilization strategies of pharmaceutical proteins[J]. Pharmaceutics, 2022, 14(11):2533.
[25] EISNER D R, HUI A D, EPPLER K, et al. Stability evaluation of hydrogen peroxide uptake samples from monoclonal antibody drug product aseptically filled in vapor phase hydrogen peroxide-sanitized barrier systems: a case study[J]. PDA Journal of Pharmaceutical Science and Technology, 2019, 73(3):285-291.
[26] YOU J W, ZHANG J, WANG J, et al. Cysteine-based coupling: challenges and solutions[J]. Bioconjugate Chemistry, 2021, 32(8):1525-1534.
[27] DATTA-MANNAN A, CHOI H, STOKELL D, et al. The properties of cysteine-conjugated antibody-drug conjugates are impacted by the IgG subclass[J]. The AAPS Journal, 2018, 20(6):103.
[28] PATEL J, KOTHARI R, TUNGA R, et al. Stability considerations for biopharmaceutical of part 1: overview of protein and peptide degradation pathways[J]. BioProcess International, 2011, 9(1):20-24.
[29] LI S, SCHÖNEICH C, BORCHARDT R T. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization[J]. Biotechnology and Bioengineering, 1995, 48(5):490-500.
[1] LI Xiu-e1, GAO Shu-lian2, ZHANG Qiu3*. Study of the toxicity of functionalized multi-walled carbon nanotubes to NHFB cells [J]. J4, 2010, 45(5): 6-11.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of JOURNAL OF SHANDONG UNIVERSITY(NATURAL SCIENCE)
Supported by Beijing Magtech Co.Ltd